Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

Liu, Sariah; Kurzrock, Razelle

doi:10.1016/j.ctrv.2014.05.003

Cited by 141 publications

(114 citation statements)

References 94 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Various side effects of the VEGF TKIs have been reported, including constitutional, cardiovascular, endocrinologic, gastrointestinal, cutaneous , and notably myelosuppressive effects, represented by anemia, thrombocytopenia, and/or leukopenia but not erythrocytosis (Liu and Kurzrock, 2014). Here we report 6 patients who developed symptomatic polycythemia associated with symptoms secondary to anti-VEGF treatment for RCC..…”

Section: Introductionmentioning

confidence: 88%

Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review

Wang

Cheng

Mallon

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 88%

Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review

Wang

Cheng

Mallon

et al. 2015

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…Because TT was developed to act on well-defined targets or biological pathways, initial evidence suggested that patients tolerated targeted therapies better than traditional CTX (19). In addition, survival rates increased in patients with GI cancers who received TT (20).…”

Section: Introductionmentioning

confidence: 99%

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Tantoy

Dhruva

Cataldo

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: Approximately 28% of patients with gastrointestinal (GI) cancers will receive targeted therapy (TT) because of the associated increases in survival. Only four studies have examined the symptom experience of these patients. To date, no studies have evaluated for differences in symptom occurrence, severity, and distress between patients who received chemotherapy (CTX) alone (n=304) or CTX with TT (n=93).Methods: Patients completed self-report questionnaires, approximately one week after they received CTX.A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to obtain data on symptom occurrence, severity, and distress. Binary logistic regression analyses were used to test for differences in symptom occurrence rates between the two treatment groups. Ordinal logistic regression analyses were used to test for differences in severity and distress ratings between the two treatment groups.Results: Patients who received CTX with TT were significantly younger (P=0.009); were diagnosed with cancer longer (P=0.004); had a higher number of prior treatments (P=0.024); had metastatic disease, specifically to the liver (P<0.001); had a diagnosis of anal, colon, rectum, or colorectal cancer (CRC) (P<0.001); and were positive for detection of B-Raf proto-oncogene, serine/threonine kinase (BRAF) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations (both P<0.001). In addition, CTX treatment regimens were significantly different between the two groups (P<0.001). After controlling for significant covariates, patients who received TT reported lower occurrence rates for lack of energy, cough, feeling drowsy, and difficulty sleeping (all, P<0.05). Patients who received TT reported lower severity scores for dry mouth (P=0.034) and change in the way food tastes (P=0.035). However, they reported higher severity scores for "I don't look like myself" (P=0.026).No differences in symptom distress scores were found between the two treatment groups.Conclusions: This study is the first to evaluate for differences in the symptom experience of GI cancer patients who received CTX alone or CTX with TT using a multidimensional symptom assessment scale.While between group differences in patients' symptom experiences were identified, both treatment groups warrant ongoing assessments to optimally manage their symptoms.

show abstract

“…Although safety concerns are substantiated [21][22][23], oncology treatments are applied in general practice to patients with conditions that would preclude enrollment in RCTs. While oncologists do not use medications in situations where absolute contraindications exist, patients with relative contraindications who would be excluded in RCTs may receive treatment in general practice.…”

Section: Discussionmentioning

confidence: 99%

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Srikanthan

Vera‐Badillo

Ethier

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms

Cited by 141 publications

References 94 publications

Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review

Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review

Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies

Contact Info

Product

Resources

About